title: Intravesical treatment with cis-urocanic acid improves bladder function in rat model of acute bladder inflammation.
abstract: The aim was to study the effect of intravesically instilled cis-urocanic acid (cis-UCA) on bladder function in an experimental rat model of acute bladder inflammation. Hyaluronic acid (HA) was used as a comparator compound.
  
  
  
  Bladder irritation was induced in female rats by intravesical hydrochloric acid (HCl) infusion. Vehicle, 0.5% HA, or 2% cis-UCA solutions were infused intravesically twice a day for three consequent days. On the fourth day, urodynamical measurements were performed, the animals were sacrificed, and the bladders were removed for histopathological assessment.
  
  
  
  HCl treatment caused significant impairment of bladder function indicated by decreased micturition intervals and voided urine volumes and induced severe voiding dysfunction observed as occurrence of overflow incontinence. These functional changes were accompanied by increased bladder weight, hemorrhage, and infiltration of inflammatory cells into the urothelium. Intravesical cis-UCA treatment recovered bladder function by significantly prolonging the micturition interval, increasing the voided volume, and reducing the occurrence of overflow incontinence. All these changes were comparable to the effects of HA.
  
  
  
  Intravesical administration of cis-UCA was able to partially recover bladder function impaired by chemical irritation. Cis-UCA may offer a novel intravesical treatment option in some inflammatory conditions of the bladder. Neurourol. Urodynam. 35:786-791, 2016. © 2015 Wiley Periodicals, Inc.
authors.affiliation: Pharmatest Services Ltd., Turku, Finland.|Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turuk, Finland.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Konkol
authors.affiliation: Pharmatest Services Ltd., Turku, Finland.
authors.forename: Jenni
authors.initials: J
authors.lastname: Bernoulli
authors.affiliation: Department of Biology, Laboratory of Animal Physiology and Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
authors.forename: Tomi
authors.initials: T
authors.lastname: Streng
authors.affiliation: BioCis Pharma Ltd., Turku, Finland.
authors.forename: Katarina
authors.initials: K
authors.lastname: Jääskeläinen
authors.affiliation: BioCis Pharma Ltd., Turku, Finland.
authors.forename: Jarmo
authors.initials: J
authors.lastname: Laihia
authors.affiliation: BioCis Pharma Ltd., Turku, Finland.
authors.forename: Lasse
authors.initials: L
authors.lastname: Leino
mesh_terms: D000283:Administration, Intravesical; D000818:Animals; D003556:Cystitis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D006820:Hyaluronic Acid / Q000494:pharmacology; D006851:Hydrochloric Acid; D051381:Rats; D017207:Rats, Sprague-Dawley; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects* / Q000502:physiology; D014560:Urocanic Acid / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D006820:Hyaluronic Acid; D014560:Urocanic Acid; D006851:Hydrochloric Acid
keywords: administration; cis-urocanic acid; cystitis; drug evaluation; interstitial; intravesical; preclinical; urinary tract